We’ve got new preclinical data showing persistent in vivo editing and durability using our in vivo #CRISPR/ Cas9 technology at this week’s Annual @OTSociety Meeting. Tune into Intellia Sr. Director Tony Forget’s presentation today. https://ir.intelliatx.com/news-releases/